Table 1.
Inhibitory activity of C11‐6’ and C11‐3’ against different influenza strains
| Compound | CC50 [µg mL−1] | EC50 [µg mL−1] | EC50 a) [nm] | |
|---|---|---|---|---|
| A/Netherlands/602/2009 (H1N1) | C11‐6’ | >100 | 0.18 (0.14 – 0.24) | 42 |
| C11‐3’ | >100 | 6.5 (4.1‐10.1) | >1000 | |
| A/Switzerland/8337/2018‐MDCK1 (H1N1) | C11‐6’ | >100 | 0.5 (0.4 – 0.67) | 125 |
| A/Singapore/37/2004 (H3N2) | C11‐6’ | >100 | 0.23 (0.16 – 0.34) | 56.5 |
| B/Wisconsin/01/2010 b) | C11‐6’ | >100 | 2.2 (1.49 – 3.42) | 500 |
| B/Switzerland/3849/2018‐MDCK1 b) | C11‐6’ | >100 | 20 (10.5 – 28.7) | >1000 |
| A/turkey/Turkey/2005 (H5N1) | C11‐3’ | >100 | 4.1 (2.55‐6.7) | 931 |
| C11‐6 | >100 | N/A | N/A | |
| A/turkey/Italy/1999 (H7N1) | C11‐3’ | >100 | 8.8 (3.2‐26) | >1000 |
| HSV‐2 (Control) | C11‐6’ | >100 | N/A | N/A |
a)
Molar concentrations were determined based on the modified cyclodextrins
b)
B Yamagata lineage
CC50: Half‐cytotoxic concentration. EC50: Half‐effective concentration with 95% CI in brackets. N/A: not assessable